ONCY Stock Forecast & Price Target

Oncolytics Biotech is supported by a sharpened, capital-efficient strategy that concentrates resources on FDA-aligned gastrointestinal programs, especially the randomized Phase 2 REO 033 study in 2L RAS-mutated MSS mCRC and the planned pivotal SCAC trial, both of which could support accelerated and traditional approval within single studies. The investment case is strengthened by encouraging efficacy signals, including a 33% ORR, 19.5-month duration of response, 16.6-month median PFS, and 27-month median OS in mCRC versus much lower historical benchmarks, alongside translational data showing immune-priming and expansion of mutant KRAS-specific TIL clones. Although cash and cash equivalents were only $4.1 million as of June 30 and mPDAC remains partner-dependent, the regulatory alignment, site activation progress, and potential year-end 2026 data readout make the pipeline look increasingly de-risked and commercially relevant.

Oncolytics Biotech is viewed negatively because the GOBLET Cohort 4 readout timing has loosened, delaying a near-term SCAC catalyst and leaving investors dependent on a partner-gated pathway rather than a clear company-controlled milestone. The thesis is further weakened by the 2Q26 10-Q updates, which lowered the risk-adjusted firm value to about $0.7 billion and cut the valuation framework materially as probabilities of success were reduced, including anal cancer to 10% from 40%, while colorectal cancer remains only 40%. In addition, the model assumes annual gross equity raises of roughly $50 million to $100 million from 2026E-2029E, signaling persistent dilution risk on top of clinical, competitive, and capital market uncertainty.